Maravai LifeSciences saw the highest growth of 99% in patent filings and 199% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 99% and grants by 199%. GlobalData’s DataBook provides a comprehensive analysis of Maravai LifeSciences‘s patent filings and grants. Buy the databook here.
Maravai LifeSciences has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 50% filings and 40% grants. The European Patent Office(EPO), Denmark(DK), Finland(FI), and Lithuania(LT) patent Office are among the top ten patent offices where Maravai LifeSciences is filings its patents. Among the top granted patent authorities, Maravai LifeSciences has 40% of its grants in European Patent Office(EPO), 40% in Finland(FI) and 20% in Lithuania(LT).
Ionis Pharmaceuticals and Alnylam Pharmaceuticals could be the strongest competitors for Maravai LifeSciences
See Also:
Patents related to health & wellness lead Maravai LifeSciences's portfolio
Maravai LifeSciences has the highest number of patents in health & wellness. For health & wellness, nearly 100% of patents were filed and 100% of patents were granted in Q4 2023.
Food related patents lead Maravai LifeSciences portfolio
Maravai LifeSciences has highest number of patents in food. For food, nearly 100% of patents were filed and 100% of patents were granted in Q4 2023.
For comprehensive analysis of Maravai LifeSciences's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.